Closing the Earnings Gap
According to Boston Consulting Group, patent expirations and market pressures mean that the existing pipeline of drugs will generate an average of only 5.5% annual earnings growth--less than half the 13% necessary to meet shareholder expectations. To grow earnings at the required rate, companies need to pursue a combination of new product strategies, improving margins through cost reductions and growing existing products.
You may also be interested in...
A draft EU guideline explains how disease registries can be used to supplement evidence in the pre-authorization phase and provide infrastructure for post-authorization evidence generation.
Drug companies have their last chance to negotiate which documents and information Italy’s regulator, AIFA, will be entitled to request of them when they submit pricing and reimbursement applications.
Sandoz sees key opportunities ahead in both the US and Canadian biosimilars markets, the firm’s US vice-president for marketing, market access and patient services, Sheila Frame, tells Generics Bulletin in the second part of an exclusive interview.